O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort

首页> 外文期刊>Journal of viral hepatitis. >O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort

【24h】

O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort

机译：O-028：直接作用抗病毒HCV治疗对肝硬化的患者安全有效：来自HCV-Target Cohort的真实世界经验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of viral hepatitis.》 |2018年第s1期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort [J] . Journal of viral hepatitis. . 2018,第S1期

机译：O-028：直接作用抗病毒HCV治疗对肝硬化的患者安全有效：来自HCV-Target Cohort的真实世界经验
2. High efficacy of the currently recommended regimens of 2 Direct Acting Antivirals (DAAs) +/- Ribavirin (R) in HCV genotype 4 (GT4) patients (pts) with advanced fibrosis or cirrhosis in HERACLIS real world cohort [J] . Goulis Ioannis, Elefsiniotis Ioannis, Karatapanis Stylianos, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：目前推荐的2个直接作用抗病毒（DAAS）+/-利巴韦林（R）在HCV基因型4（GT4）患者（PTS）中具有晚期纤维化或Heraclis Real World Cohort的肝硬化的高疗效
3. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network ActivityLINA cohort) [J] . Gentile Ivan, Scotto Riccardo, Coppola Carmine, Hepatology international . 2019,第1期

机译：用直效抗病毒治疗改善了HCV相关的失代偿性肝硬化患者的临床结果：意大利现实队列的结果（肝脏网络致敏LINA COHORT）
4. A study on the fluctuation of HCV antigens during hemodialysis therapy of dialysis patients with the HCV infection using Langmuir's adsorption isotherm [C] . Kotera Hirohisa, Yashiro Masatomo, Ohashi Atsushi, 2012 ICME International Conference on Complex Medical Engineering . 2012

机译：用朗缪尔吸附等温线研究血液透析患者HCV感染过程中HCV抗原的波动
5. The Distribution of Change over Time in Metabolic, Inflammatory, and Immune Parameters in HCV-monoinfected and HIV/HCV-coinfected Patients Cured of Hepatitis C Virus by Direct-Acting Antiviral Therapy [D] . Emmanuel, Benjamin. 2018

机译：通过直接作用抗病毒治疗，在HCV-单染料和HCV / HCV / HCV-焦收的患者中的代谢，炎症和免疫参数随时间随时间的分布，通过直接作用抗病毒治疗治愈丙型肝炎病毒
6. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India [O] . Gaurav Garg, Vinod K. Dixit, Sunit K. Shukla, 2018

机译：直接作用的抗病毒药物对未治疗的HCV肝硬化的治疗对肝纤维化和严重程度的影响：来自印度北部三级护理中心的真实生活经验
7. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia [O] . Ligita Jancoriene, Katazyna Polubenko, Edita Kazenaite, 2018

机译：直接作用抗病毒药虫/ paritabrevir / ritonavir + dasabuvir在丙啶病毒（hcv）基因虫中（hcv）基因型1-感染的治疗 - 幼稚或治疗 - 经验丰富的患者或没有肝硬化的患者：立陶宛和拉脱维亚的现实生活经验

O‐028: Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV‐TARGET cohort

著录项

相似文献

相关主题

期刊订阅